Pain Therapeutics (NASDAQ:PTIE) shares fell 3.8% during trading on Tuesday . The company traded as low as $2.49 and last traded at $2.51, with a volume of 77,022 shares changing hands. The stock had previously closed at $2.61.

Separately, Zacks Investment Research downgraded shares of Pain Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th.

The company’s 50-day moving average price is $2.37 and its 200-day moving average price is $2.18. The firm’s market cap is $116.74 million.

Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings results on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.07. On average, analysts expect that Pain Therapeutics will post ($0.42) earnings per share for the current fiscal year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.